Pharmacological and Neuromodulatory Strategies Following SSRI Non-Response in Major Depressive Disorder: Divergent U.S. and European Treatment Pathways and the Emerging Role of Novel FDA-Approved Interventions

 I. López-Ibor, MD

Clínica López-Ibor, Madrid, Spain. Sanatorio del Dr Esquerdo, Madrid, Spain. Clinica del Dr Leon, Madrid, Spain. South Florida Integrative Medicine, Miami, Florida. 

Correspondence: drivanlopezibor@gmail.com

Abstract

Selective serotonin reuptake inhibitors (SSRIs) remain the cornerstone of first-line pharmacotherapy for major depressive disorder (MDD); however, remission following an initial adequate SSRI trial remains limited in routine clinical practice. When SSRI response is insufficient, treatment pathways diverge substantially between the United States and Europe, reflecting not only regulatory differences but fundamentally distinct conceptual frameworks for understanding antidepressant non-response.

Over the past five years, U.S. clinical practice has progressively shifted toward earlier augmentation, broad mechanism diversification, and integration of novel FDA-approved pharmacological agents targeting glutamatergic, sigma-1, and dopaminergic systems. Concurrently, device-based interventions — including repetitive transcranial magnetic stimulation (rTMS), deep TMS, esketamine nasal spray, vagus nerve stimulation (VNS), and emerging home-use neurostimulation technologies — have been incorporated at earlier treatment stages.

In contrast, European clinical practice continues to emphasize sequential antidepressant switching within monoaminergic frameworks, delayed augmentation strategies, and comparatively restricted access to recently approved therapeutic modalities. This transatlantic divergence may affect clinical outcomes more profoundly than previously appreciated.

This narrative review examines contemporary (2020–2026) evidence on post-SSRI treatment failure, compares U.S. and European treatment philosophies and regulatory landscapes, and summarizes novel FDA-approved pharmacological and device-based interventions currently reshaping depression management.

Keywords: major depressive disorder; SSRI non-response; treatment-resistant depression; augmentation; transcranial magnetic stimulation; esketamine; dextromethorphan-bupropion; neuromodulation; psychopharmacology

1. Introduction

Failure to achieve remission following an adequate selective serotonin reuptake inhibitor (SSRI) trial represents one of the most clinically significant decision points in the management of major depressive disorder (MDD). Despite the central role that SSRIs have occupied in pharmacotherapy for over three decades, real-world remission rates following first-line treatment remain modest. Data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial and subsequent real-world cohorts consistently demonstrate progressive attrition of response rates across sequential treatment steps, with remission rates declining from approximately 37% after the first step to below 15% after the third (1,2).

Although contemporary international guidelines broadly converge on core principles — including confirmation of treatment adequacy, systematic reassessment of the primary diagnosis, and staged therapeutic escalation — the practical implementation of these principles differs considerably across healthcare systems (2,3). Nowhere is this divergence more clinically consequential than in post-SSRI management.

The United States has increasingly adopted a mechanism-diversification model characterized by earlier augmentation, rapid integration of multimodal antidepressants, deployment of glutamatergic agents, and broader utilization of circuit-based neuromodulation. European practice, by contrast, remains comparatively conservative, favoring serial antidepressant switching, delayed augmentation, and more restricted access to advanced interventions. This divergence reflects not only differential regulatory approval but also fundamentally distinct conceptualizations of treatment failure and therapeutic escalation.

This disparity has become increasingly clinically relevant as multiple FDA approvals since 2022 have introduced therapeutic agents targeting glutamatergic, sigma-1, and dopaminergic pathways, alongside expanded indications for device-based neuromodulation — many of which remain absent or operationally inaccessible in European healthcare systems. The present review synthesizes current evidence and provides a structured comparative analysis of post-SSRI treatment strategies across these two major clinical traditions.

2. Why SSRI Non-Response Represents a Strategic Decision Point

SSRI non-response is not a homogeneous clinical phenomenon. Apparent treatment failure may reflect a range of distinct underlying processes, each with different clinical implications:

• Inadequate pharmacological exposure due to subtherapeutic dosing or insufficient trial duration
• Pharmacokinetic variability driven by cytochrome P450 polymorphisms affecting drug metabolism
• Diagnostic misclassification, including unrecognized bipolarity, comorbid personality pathology, or primary anxiety disorders
• True pharmacodynamic non-response reflecting individual biological heterogeneity
• Ongoing psychosocial stressors or inadequately treated comorbid medical conditions (3,4)

Contemporary U.S. frameworks increasingly treat SSRI failure as a clinically meaningful signal to diversify neurobiological targets rather than to repeat serotonergic strategies. This conceptual shift — from serotonin optimization to mechanism diversification — constitutes the central difference between U.S. and European approaches to post-SSRI management.

Following inadequate SSRI response, clinicians broadly face three strategic options: (1) optimization of the serotonergic strategy through dose adjustment, duration extension, or within-class switching; (2) diversification of neurobiological mechanism through addition of norepinephrinergic, dopaminergic, glutamatergic, or multimodal agents; or (3) transition to circuit-based intervention through TMS, ketamine or esketamine, VNS, or ECT. The principal difference between U.S. and European practice lies in the threshold and pace at which clinicians transition from the first to the second and third options.

3. Strategic Differences: United States vs. Europe

3.1 United States: Augment-Early, Diversify-Fast Model

Contemporary U.S. practice increasingly conceptualizes partial SSRI response as evidence of partial biological engagement — a signal to enhance and diversify active pathways rather than abandon them. This augmentation-first philosophy has been reinforced by STAR*D data demonstrating limited incremental benefit from continued monoaminergic switching and by the progressive availability of mechanistically distinct pharmacological options (1,5).

Typical U.S. post-SSRI pathways in partial responders favor augmentation with atypical antipsychotics (brexpiprazole, aripiprazole, cariprazine), bupropion, mirtazapine, or lithium, often prior to switching. In cases of complete non-response, mechanism switching — to SNRIs, vortioxetine, or glutamatergic agents — is prioritized over repeated serotonergic trials. In recurrent or severe failure, early referral to interventional psychiatry for TMS or esketamine is increasingly standard practice at academic and specialty centers.

3.2 Europe: Sequential Switch Model

European practice, as reflected in guidelines from the World Federation of Societies of Biological Psychiatry (WFSBP) and major national bodies, continues to emphasize sequential antidepressant switching within monoaminergic frameworks (3). Augmentation strategies are typically introduced later in the treatment sequence, and access to neuromodulation and ketamine-based therapies remains inconsistent across healthcare systems.

This model prioritizes pharmacological simplicity and conservative escalation. However, its principal limitation is the risk of prolonged patient exposure to ineffective treatment trials, delayed remission, and restricted access to mechanistically novel therapies that may offer benefit to biologically distinct patient subgroups.

4. Novel FDA-Approved Pharmacological Options Not Broadly Available in Europe

4.1 Dextromethorphan-Bupropion (Auvelity®)

Dextromethorphan-bupropion received FDA approval in 2022 and represents the most pharmacologically innovative antidepressant approval in recent years. Its mechanism combines NMDA receptor antagonism and sigma-1 receptor agonism (via dextromethorphan) with norepinephrine and dopamine reuptake inhibition (via bupropion). Bupropion also serves as a CYP2D6 inhibitor, increasing dextromethorphan bioavailability through reduced first-pass metabolism.

Clinical trial data demonstrated meaningful antidepressant effects within one to two weeks, a substantially more rapid onset than conventional monoaminergic antidepressants. Dextromethorphan-bupropion is the first oral antidepressant to achieve widespread clinical adoption on the basis of glutamatergic — rather than serotonergic — modulation, and represents a paradigm-relevant option for patients who have failed SSRI trials (6). The compound is not broadly approved or commercially available across European markets as of 2025.

4.2 Cariprazine — Adjunctive MDD Indication

Cariprazine, a D3-preferring dopamine partial agonist originally approved for schizophrenia and bipolar disorder, received expanded FDA approval for adjunctive treatment of MDD. Its preferential activity at D3 receptors in mesolimbic dopaminergic circuits provides a mechanistically distinct augmentation strategy particularly relevant for depressive phenotypes characterized by anhedonia, motivational impairment, and psychomotor slowing (7). Its availability and positioning for MDD augmentation in Europe remain limited.

4.3 Brexpiprazole

Brexpiprazole is widely used as an adjunctive agent in partial SSRI responders in U.S. clinical practice. Compared to aripiprazole, brexpiprazole carries a lower risk of akathisia and activation, which enhances tolerability in patients with anxiety-prominent depressive presentations. Although available in several European markets, its integration into mainstream European augmentation algorithms remains less established than in the United States (8).

4.4 Esketamine (Spravato®)

Intranasal esketamine received FDA approval for treatment-resistant depression (TRD) and, subsequently, for depressive symptoms associated with acute suicidality. Its mechanism involves rapid modulation of glutamatergic transmission via NMDA receptor antagonism, producing clinically meaningful symptom reduction within hours to days — a profile without precedent in conventional antidepressant pharmacology (9).

Although esketamine is approved in Europe, implementation differs substantially in terms of center availability, reimbursement frameworks, and referral thresholds. In the United States, it is increasingly integrated at earlier stages of the treatment algorithm in specialty psychiatric settings.

4.5 Emerging Glutamatergic Pipeline

The United States market continues to generate investigational glutamatergic compounds, including oral NMDA modulators, AMPA potentiators, and neurosteroid-based agents. This pipeline reinforces the trajectory of U.S. pharmacological development toward mechanism diversification beyond the serotonin-norepinephrine axis, a trend that has not yet been replicated with comparable pace in the European regulatory landscape.

5. Device-Based Interventions Following SSRI Failure

5.1 Repetitive Transcranial Magnetic Stimulation (rTMS)

Repetitive TMS targeting the left dorsolateral prefrontal cortex (DLPFC) is FDA-cleared for MDD following inadequate response to antidepressant pharmacotherapy and represents the most widely adopted circuit-based intervention in U.S. clinical practice. Its evidence base has expanded substantially since 2020, with robust data supporting its efficacy across multiple treatment protocols including standard high-frequency, low-frequency contralateral, and intermittent theta-burst stimulation (iTBS) paradigms (10). In the United States, rTMS is commonly introduced after one to two failed pharmacological trials. European access and reimbursement remain highly variable by country and healthcare system.

5.2 Deep TMS

Deep TMS using H-coil technology enables stimulation of deeper cortical targets compared to standard figure-8 coils. It has received FDA clearance for MDD and obsessive-compulsive disorder, and is increasingly adopted in U.S. specialty centers managing anxious and treatment-resistant depressive presentations. Its broader cortical penetration may be clinically advantageous in patients with predominant anterior cingulate or subcortical circuit pathology (10).

5.3 Vagus Nerve Stimulation (VNS)

Implantable VNS is FDA-approved for chronic treatment-resistant depression and provides long-horizon neuromodulatory effects through afferent vagal projections to limbic and prefrontal circuits. Although underutilized relative to its evidence base, VNS represents an important option for patients with recurrent, chronic TRD who have failed multiple pharmacological and non-invasive neuromodulatory interventions (11).

5.4 Home-Use Neurostimulation (Emerging)

Recent FDA clearances for home-use transcranial electrical stimulation devices represent a potentially significant shift in the post-SSRI treatment landscape. The emergence of scalable, patient-administered neurostimulation technologies may substantially lower barriers to circuit-based intervention and expand access beyond specialty psychiatric centers. The clinical integration of these devices is currently in early stages, but they may constitute a major future divergence between U.S. and European treatment accessibility.

5.5 Electroconvulsive Therapy (ECT)

ECT remains the highest-efficacy intervention available for severe MDD, psychotic depression, catatonia, and acute suicidality refractory to pharmacotherapy. Despite its robust evidence base, utilization continues to be constrained by persistent clinical stigma and logistical barriers disproportionate to the strength of its therapeutic profile. Its delayed deployment in clinical practice reflects cultural rather than evidence-based considerations in both the United States and Europe.

6. Conceptual Shift: From Monoamines to Circuits

The most clinically meaningful evolution in post-SSRI management over the past decade is not the introduction of individual new agents, but rather a broader reconceptualization of the therapeutic target. The historical monoamine model — in which antidepressant treatment was fundamentally equated with increasing synaptic serotonin or norepinephrine availability — has progressively given way to a circuit-based framework that conceptualizes MDD as a disorder of dysfunctional connectivity across cortical, limbic, and subcortical networks.

Within this emerging framework, the relevant clinical question following SSRI failure is no longer simply 'which antidepressant next?' but rather 'which neurobiological system or neural circuit has not yet been meaningfully targeted?' This reframing enables more systematic, mechanism-informed treatment selection and provides a principled rationale for earlier integration of glutamatergic pharmacology and circuit-based neuromodulation.

The United States has moved substantially further into this third conceptual phase — characterized by mechanism diversification, circuit-level targeting, and rapid-acting pharmacological strategies. European practice largely remains between the first and second phases, with monoaminergic optimization continuing to anchor most algorithmic pathways.

7. Limitations

This review has several limitations that should be acknowledged. As a narrative review, it does not employ systematic search methodology or meta-analytic synthesis, and is therefore susceptible to selection bias in the evidence reviewed. The characterization of European and U.S. treatment practice as unified models necessarily obscures substantial heterogeneity within each region — clinical practice varies considerably across European healthcare systems and between U.S. academic and community settings.

Furthermore, regulatory approval and clinical availability are dynamic; the landscape described here reflects the best available evidence through early 2026 and is subject to change. Direct comparative outcome data between U.S. and European post-SSRI treatment pathways remain limited, and the clinical significance of the strategic differences described here has not been formally quantified in prospective comparative trials.

8. Conclusion

Post-SSRI treatment failure increasingly exposes a transatlantic divide in depression management that reflects not only differential regulatory approval but fundamentally distinct clinical philosophies. The United States has embraced earlier augmentation, glutamatergic pharmacology, dopaminergic targeting, and device-based neuromodulation as standard components of the post-SSRI treatment algorithm. European practice continues to rely more heavily on sequential monoaminergic strategies, with delayed access to mechanistically novel interventions.

Current evidence suggests that this divergence is driven more by differences in therapeutic philosophy, regulatory pace, and healthcare system structure than by differences in the underlying scientific evidence base. As novel FDA-approved pharmacological and neuromodulatory therapies continue to expand, the management of SSRI non-response is transitioning from a serotonin-centered model toward a multimodal, mechanism-informed, and circuit-based framework. Prospective comparative research across healthcare systems is warranted to determine whether these strategic differences translate into clinically meaningful differences in patient outcomes.

Declarations

Conflict of interest: The author declares no conflicts of interest.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Ethics approval: Not applicable (narrative review).

Author contributions: Iván López-Ibor: conceptualization, literature review, writing — original draft, writing — review and editing.

References

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.

2. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 clinical guidelines for the management of major depressive disorder in adults. Can J Psychiatry. 2023.

3. Bauer M, Severus E, Köhler S, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of unipolar depressive disorders — update 2022. World J Biol Psychiatry. 2022.

4. McIntyre RS, Rosenblat JD. Mechanism-based treatment selection in major depressive disorder. Lancet Psychiatry. 2024.

5. Gaynes BN, Rush AJ, Trivedi MH, et al. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75(1):57–66.

6. Tabuteau H, Jones A, Anderson A, et al. Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022;179(7):490–499.

7. Thase ME, Youakim JM, Skuban A, et al. Adjunctive cariprazine in patients with major depressive disorder: a placebo-controlled phase III study. J Clin Psychiatry. 2023.

8. Clayton AH, Durgam S, Tang X, et al. Brexpiprazole as adjunctive treatment for major depressive disorder. CNS Spectr. 2023.

9. Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression. JAMA Psychiatry. 2021;78(2):141–149.

10. Perera T, George MS, Grammer G, et al. The Clinical TMS Society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul. 2021.

11. Aaronson ST, Carpenter LL, Conway CR, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression. Brain Stimul. 2021. 

12. Nemeroff CB. The state of our understanding of the pathophysiology and optimal treatment of depression. Am J Psychiatry. 2020;177(8):671–682.